News

The two backbones of CGeneTech won new honors in the third Jinji Lake skill Invitational Competition

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2022-02-22
  • Views:0

(Summary description)During the anti epidemic campaign in Suzhou, we can see that medical work is inseparable from excellent analytical and technical personnel. Recently, good news came from the 11th high skill competition and the 3rd Jinjihu skill Invitational Competition: two technical backbones of CGeneTech's new drug R & D - Analysis Department passed all the way and won the second prize in the final of biochemical pharmaceutical engineering technology (staff group) team competition.

The two backbones of CGeneTech won new honors in the third Jinji Lake skill Invitational Competition

(Summary description)During the anti epidemic campaign in Suzhou, we can see that medical work is inseparable from excellent analytical and technical personnel. Recently, good news came from the 11th high skill competition and the 3rd Jinjihu skill Invitational Competition: two technical backbones of CGeneTech's new drug R & D - Analysis Department passed all the way and won the second prize in the final of biochemical pharmaceutical engineering technology (staff group) team competition.

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2022-02-22
  • Views:0

During the anti epidemic campaign in Suzhou, we can see that medical work is inseparable from excellent analytical and technical personnel. Recently, good news came from the 11th high skill competition and the 3rd Jinjihu skill Invitational Competition: two technical backbones of CGeneTech's new drug R & D - Analysis Department passed all the way and won the second prize in the final of biochemical pharmaceutical engineering technology (staff group) team competition.

1

In 2021, the 11th high skill competition and the 3rd Jinji Lake skill Invitational Competition opened 22 events with the theme of "technology inherits ingenuity and creates the future". The competition closely follows the demand for skilled talents in the development of key industries and emerging industries in the park. Since its launch, it has attracted more than 6600 players, and finally 2927 people entered the finals.

1

High quality talent reserve is a necessary factor for enterprise innovation. Two key employees of Shengshi Tyco's new drug R & D - Analysis Department participated in the third Jinji Lake skill Invitational Competition - "Baituo Agilent Cup" biomedical chromatographic analysis technology national open challenge. After fierce competition in the preliminary and final, they finally won the second prize in the final of biochemical pharmaceutical engineering technology (staff group) team competition.1

Founded in Suzhou Industrial Park in 2010, CGeneTech is a biotechnology company committed to the research and development of small molecule drugs in the fields of hypoglycemic, antitumor and rare diseases.
Since its establishment, the company has built a rich pipeline of class 1 innovative drugs. Its self-developed shenggliptin phosphate is a new DPP-4 inhibitor, which is in phase 3 clinical practice. It is expected that all subjects will complete phase 3 clinical practice in the middle of 2022. From the results of the subjects who completed the trial, shenggliptin phosphate showed good safety and the effect of reducing glycosylated hemoglobin. If it reaches the end point of clinical efficacy, its approval will fill the gap of domestic production of DPP-4 inhibitors (now approved are imported and registered), and has broad market prospects.


Not long ago, CGeneTech generic telifloxamine tablets were officially approved in China. The approved indication is recurrent multiple sclerosis, which is the first domestic telifloxamine approved for listing in China. After listing, it will bring high-quality and more accessible therapeutic drugs to domestic patients.

 

The

The listing application of Shengshi Tyco's new hypoglycemic drug Shenggliptin was accepted

Today, Shengshi Tyco has accepted the marketing application (NDA) of Shenggliptin, a DPP-4 inhibitor, submitted to the National Drug Administration (NMPA) for the treatment of type 2 diabetes.
2023-02-02
Quantity

"Quantity" Half Achieves Double Prosperity: Tyco's Class 1 New Hypoglycemic Drug Shenggliptin Uncovers Blindness Data

Today, Shengshi Tyco has completed a key clinical study on a class 1 new hypoglycemic drug under development: phase III clinical trial of DPP-4 inhibitor shenggliptin in the treatment of type 2 diabetes. A dose of 50mg can reach the preset end point of the trial. A therapeutic dose of "half the dose" will further improve the safety of this drug and is expected to become the best hypoglycemic drug in the same class.
2022-10-17

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO